Eli Lilly & Co., US5324571083

Lam Research Stock (US5324571083): Q4 CY2025 Revenue Beats Estimates at $5.34 Billion

05.05.2026 - 13:06:08 | ad-hoc-news.de

Lam Research reported Q4 CY2025 revenue of $5.34 billion, surpassing analyst estimates by 1.8% with 22.1% year-on-year growth. The company guided for Q1 CY2026 revenue of $5.7 billion, exceeding expectations.

Eli Lilly & Co., US5324571083
Eli Lilly & Co., US5324571083

Lam Research announced its Q4 CY2025 results, posting revenue of $5.34 billion against analyst estimates of $5.25 billion, according to data from permitted secondary sources covering the earnings release.

The results reflect 22.1% year-on-year growth for the quarter ending in CY2025. Adjusted EPS came in at $1.27, beating consensus estimates of $1.17 by 8.7%.

As of: May 05, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

  • Name: Lam Research
  • ISIN: US5324571083
  • Sector/Industry: Semiconductor Equipment
  • Headquarters/Country: Fremont, CA, United States
  • Primary Exchange: NASDAQ
  • Trading Currency: USD
  • Last Quarterly Results: Q4 CY2025, revenue $5.34 billion

How Lam Research Makes Money: The Core Business Model

Lam Research supplies wafer fabrication equipment and services to the semiconductor industry. The company focuses on production-proven manufacturing capabilities for markets including complementary metal-oxide-semiconductor image sensors and micro-electromechanical systems.

Revenue is generated through sales of equipment used in semiconductor processes. Services also contribute to the top line, supporting ongoing production needs in the sector.

The business model centers on advanced technology solutions for chip manufacturing, serving global semiconductor producers.

Lam Research's Key Revenue and Product Drivers

For Q4 CY2025, revenue reached $5.34 billion, up 22.1% year-over-year from the prior corresponding quarter. This marked the seventh straight quarter of growth.

Gross profit margin stood at 49.6% for the quarter, an increase of 2.2 percentage points from 47.4% in the same period last year. Operating margin was 33.9%, up 3.4 percentage points year-on-year.

Guidance for Q1 CY2026 projects revenue at $5.7 billion midpoint, representing 20.8% year-on-year growth. Adjusted EPS guidance is $1.35 at midpoint.

Industry Trends and Competitive Landscape

The semiconductor equipment sector supports growing demand for advanced chips. Lam Research operates in a cyclical market driven by technology upcycles, typically lasting 8-10 quarters.

Key trends include expansion in wafer fabrication capacity amid AI and data center demands. The company benefits from sustained industry investment.

Competitors in wafer fabrication equipment include established players in etch, deposition, and clean processes, verified through industry reports.

Why Lam Research Matters to US Investors

Lam Research trades on NASDAQ under ticker LRCX in USD, providing direct exposure for US investors to the semiconductor equipment sector. The company files with the SEC, ensuring transparency.

Headquartered in Fremont, California, it serves US-based chipmakers and global leaders with significant US revenue exposure. Inclusion in major indices like Nasdaq 100 adds relevance.

USD denomination eliminates direct FX risk for US portfolios focused on domestic tech infrastructure.

Which Investor Profile Fits Lam Research – and Which Does Not?

Investors tracking semiconductor supply chain growth may monitor Lam Research for its role in wafer fabrication. Those focused on cyclical tech sectors find alignment with upcycle dynamics.

Profiles seeking stable dividend payers or non-cyclical industries may look elsewhere, given the sector's volatility tied to chip demand cycles.

Long-term technology exposure suits those comfortable with industry consolidation trends.

Risks and Open Questions for Lam Research

Semiconductor markets face cyclical downturns following upcycles. Demand fluctuations from end markets like memory and logic chips pose variability.

Supply chain disruptions and geopolitical tensions in tech hardware manufacturing remain concerns. Capacity utilization shifts can impact equipment orders.

Competition in advanced process technologies requires ongoing R&D investment.

Conclusion

Lam Research's Q4 CY2025 results showed revenue of $5.34 billion beating estimates with strong growth and positive Q1 CY2026 guidance. The performance underscores ongoing upcycle momentum in semiconductor equipment. US investors gain exposure via NASDAQ listing and SEC oversight.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

So schätzen die Börsenprofis Eli Lilly & Co. Aktien ein!

<b>So schätzen die Börsenprofis  Eli Lilly &amp; Co. Aktien ein!</b>
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
en | US5324571083 | ELI LILLY & CO. | boerse | 69280531 | bgmi